Chromocell Therapeutics Corporation (CHRO)

NYSEAMERICAN: CHRO · IEX Real-Time Price · USD

1.110

-0.040 (-3.48%)

At close: Jul 19, 2024, 4:00 PM

1.120

+0.010 (0.90%)

Pre-market: Jul 22, 2024, 4:27 AM EDT

Chromocell Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0	0	0	0	0.2
Gross Profit	0	0	0	0	0.2
Selling, General & Admin	3.05	2.74	1.1	0.5	1.32
Research & Development	2.86	2.58	0.39	0.21	0.14
Other Operating Expenses	1.97	1.54	0.83	0.13	0.09
Operating Expenses	7.88	6.86	2.32	0.84	1.55
Operating Income	-7.88	-6.86	-2.32	-0.84	-1.35
Interest Expense / Income	1.09	0.52	0.14	0	0
Other Expense / Income	-	-	-	-0.24	-0.69
Pretax Income	-8.98	-7.38	-2.46	-0.6	-0.66
Net Income	-8.98	-7.38	-2.46	-0.6	-0.66
Shares Outstanding (Basic)	5	1	0	1	-
Shares Outstanding (Diluted)	5	1	0	-	-
Shares Change	322.19%	193.25%	-60.82%	-	-
EPS (Basic)	-7.03	-5.78	-5.65	-	-
EPS (Diluted)	-7.03	-5.78	-5.65	-	-
Free Cash Flow	-2.8	-0.98	-1.57	-1.59	-3.63
Free Cash Flow Per Share	-0.60	-0.77	-3.60	-1.43	-
Gross Margin	-	-	-	-	100.00%
Operating Margin	-	-	-	-	-677.16%
Profit Margin	-	-	-	-	-330.40%
Free Cash Flow Margin	-	-	-	-	-1813.48%
EBITDA	-7.88	-6.86	-2.32	-0.6	-0.66
EBITDA Margin	-	-	-	-	-329.56%
EBIT	-7.88	-6.86	-2.32	-0.6	-0.66
EBIT Margin	-	-	-	-	-329.56%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).